Business Context and Reporting Period
Company: Immunic, Inc. (IMUX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Immunic is a late-stage biotechnology company developing novel oral therapies for neurologic and gastrointestinal diseases. The company has no approved products and has not generated product revenue. Its primary focus is the clinical development of vidofludimus calcium (IMU-838) for multiple sclerosis (MS), IMU-856 for gastrointestinal diseases (e.g., celiac disease), and IMU-381 (preclinical).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(97.2) million | $(100.5) million |
| Accumulated Deficit | $(608.6) million | $(511.4) million |
| Cash and Cash Equivalents (Year-End) | $15.5 million | $35.7 million |
| Operating Expenses | $103.2 million | $98.1 million |
| Research & Development Expenses | $82.0 million | $80.0 million |
| General & Administrative Expenses | $21.2 million | $18.0 million |
| Net Cash Used in Operating Activities | $(85.8) million | $(84.8) million |
Note: All figures in millions unless otherwise noted. The filing text does not provide specific margin data as the company has no revenue.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $3.3 million (3%) compared to 2024, primarily driven by a $6.1 million increase in other income (expense), net, due to $4.8 million in German government grant income recognized in 2025.
- Expense Growth: Total operating expenses increased by 5% ($5.2 million). Research and development expenses rose 2% ($1.9 million), while general and administrative expenses increased 18% ($3.2 million), largely due to higher personnel and legal costs.
- Cash Position: Cash and cash equivalents declined by approximately $20.2 million year-over-year, reflecting continued operating cash burn despite financing activities.
- Interest Income: Interest income decreased by $2.4 million (69%) due to a lower average cash balance.
Guidance, Outlook, and Material Events
Clinical Development Status
- Vidofludimus Calcium (IMU-838):
- Phase 3 (ENSURE): Enrollment for both ENSURE-1 and ENSURE-2 trials in relapsing MS (RMS) was completed in June 2025 (2,221 patients total). Top-line data is expected by the end of 2026.
- Phase 2 (CALLIPER): Results announced in April 2025 showed reductions in 24-week confirmed disability worsening in progressive MS (PMS). Additional data presented in late 2025 reinforced neuroprotective potential.
- IMU-856: Phase 1b data in celiac disease showed positive effects on gut architecture and a dose-dependent increase in GLP-1 levels. Further clinical testing is contingent on financing.
Capital Raising and Liquidity
- February 2026 Private Placement: Closed February 17, 2026, with net cash proceeds of approximately $187.0 million. This follows gross proceeds of ~$200 million from the sale of pre-funded warrants and common warrants.
- Outlook: Management expects the February 2026 proceeds, combined with year-end cash, to fund operations for more than 12 months.
- Previous Offerings: In 2025, the company raised ~$5.1 million (April) and ~$65 million (May) through equity offerings.
Corporate Governance and Listing Status
- Nasdaq Compliance: The company failed to meet the $1.00 minimum bid price requirement for the Nasdaq Global Select Market. Listing was transferred to the Nasdaq Capital Market in January 2026, granting an additional 180-day grace period (until June 22, 2026) to regain compliance.
- Reverse Stock Split: A proxy statement was filed in February 2026 to seek shareholder approval for a reverse stock split (ratio not less than 10:1) to regain compliance and increase authorized shares.
- Leadership Changes: CEO Dr. Daniel Vitt is transitioning to a senior executive role focused on scientific strategy; a search for a new CEO with commercial expertise has begun. Simona Skerjanec was appointed Interim Chairperson of the Board.
- Royalty Agreement: In February 2026, the company entered a Royalty Purchase Agreement where certain warrant holders exchanged ~51 million Series B warrants for a 5% synthetic royalty on future sales of vidofludimus calcium.
- Delisting Risk: Failure to regain compliance with the $1.00 bid price rule by June 22, 2026, could result in delisting.
- Financing Needs: The company expects to continue incurring significant losses and will require substantial additional capital to complete clinical trials and commercialization.
- Clinical Uncertainty: Success depends on the outcome of the Phase 3 ENSURE trials; failure to meet endpoints would materially harm the business.
- Cash Runway: Verify the sufficiency of the $187 million raised in February 2026 to fund operations through the expected end-of-2026 data readout for the Phase 3 ENSURE trials.
- Reverse Stock Split Approval: Monitor the outcome of the special shareholder meeting regarding the reverse stock split, which is critical for maintaining Nasdaq listing and future capital raising flexibility.
- Phase 3 ENSURE Data: The top-line data expected in late 2026 is the primary catalyst for regulatory approval and potential commercialization of vidofludimus calcium.
- Royalty Obligation: Assess the impact of the 5% synthetic royalty on future net sales of vidofludimus calcium resulting from the February 2026 warrant exchange.
- CEO Transition: Evaluate the progress of the CEO search and the strategic shift toward commercialization leadership.